Skip to main content
Category

News Archive

techtransf

Explore the World of Technology Transfer and Commercialization with the Technology Transfer Society – Washington D.C. Chapter

By News, News Archive

techtransfThe Technology Transfer Society – Washington D.C. Chapter is excited to announce its Fall 2024 course, “Introduction to Technology Transfer and Commercialization,” offered in collaboration with Montgomery College. This hybrid course, available both virtually and in-person, is designed to provide students with a comprehensive overview of the technology transfer process—transitioning innovations from the lab to the marketplace.

Whether you’re interested in the inner workings of a technology transfer office or looking to commercialize your own invention, this course is an excellent opportunity to gain valuable insights. You’ll learn from seasoned professionals, including experts from federal labs, who will share their knowledge and experiences to help you navigate the complexities of technology transfer.

Read More
Brain

UVA Engineering Professor’s $600,000 Grant Set to Innovate Pediatric Brain Tumor Treatment

By News, News Archive

BrainNatasha Sheybani, assistant professor of biomedical engineering at the University of Virginia School of Engineering, will collaborate with researchers at Children’s National Hospital to study the combination of two therapies for pediatric brain cancer. 

High-risk brain tumors in children often don’t respond well to existing chemotherapy and radiation treatments, but Sheybani and her collaborators hope their fusion of therapies will offer a better option. 

Read More
OSJnJ

OS Therapies Accepted Into Johnson & Johnson Innovation – JLABS

By News, News Archive

OSJnJROCKVILLE, Md.–()–OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that it has been accepted into Johnson & Johnson Innovation – JLABS. Through membership of JLABS, OS Therapies aims to further develop and enter the clinic with its tunable Antibody Drug Conjugate (ADC) linker-based platform that relies on pH sensitive linkers & coating technology to reduce off-target effects to improve safety and increase the number & diversity of therapeutic payloads delivered. Through these developments, OS Therapies hopes to offer improved efficacy versus other ADCs in the market or in development. Drug candidates developed using OS Therapies’ tunable ADC platform leverage this unique linker platform to create new intellectual property for both novel and off-patent targeting antibodies and drug payloads.

Read More
WIBlogo

Women In Bio (WIB) Excited to Participate in the 10th Annual BioHealth Capital Region Forum

By News, News Archive

WIBlogoWomen In Bio (WIB) will be well-represented at the 10th Annual BioHealth Capital Region Forum on September 17th and 18th, 2024, at US Pharmacopeia in Rockville, MD. WIB, a national organization dedicated to advancing women’s careers, leadership, and entrepreneurship in the life sciences, will host a table at this annual event as part of its in-kind partnership with BioHealth Innovation, Inc. (BHI) and the Forum planning committee. Attendees can learn more about WIB’s mission to empower women across the biohealth sector and explore opportunities to get involved in this dynamic community.

With 13 chapters across the U.S. and Canada, including the Capital Region chapter, WIB’s members include professionals from leading biotech, pharmaceutical, medical device companies, academia, government, and supporting industries like finance and law. WIB provides a robust platform for networking, mentorship, and professional development, fostering diversity and inclusion in life sciences.

Read More
AURP

AURP’s BIO Health Caucus Sponsors 10th Annual BioHealth Capital Region Forum

By News, News Archive

AURPAURP and its BIO Health Caucus have sponsored the 10th Annual BioHealth Capital Region Forum (Sept 17-18) at US Pharmacopeia in Rockville, MD.

Serving on the Forum planning committee are: Amy Adams, Executive Director of George Mason University’s Institute for Biohealth Innovation; Kolaleh Eskandanian, Vice President and Chief Innovation Officer at Children’s National Hospital; and Brian Darmody, AURP Chief Strategy Officer.

The BioHealth Capital Region Forum gathers together the DC/MD/VA region’s biopharma sector, to highlight the region’s capabilities and achievements with insights into future trends. With over 2,300 life science companies, 78 federal labs, and numerous esteemed academic institutions, the BioHealth Capital Region stands as a vibrant hub of innovation and opportunity. Learn more.

2 weeks Crab Trap

Final Week to Apply! Deadline August 30th for the 9th Annual Crab Trap Competition

By News, News Archive

2 weeks Crab Trap

This is your last chance to apply for this year’s Crab Trap Competition, taking place on September 18th, 2024, during BioHealth Capital Region Week at USP in Rockville, Maryland. This event is an incredible opportunity for startups in the biohealth sector to pitch their innovative solutions to a panel of esteemed industry leaders.

Pitch Your Innovation: Finalists will present their business models and technologies during day 2 of the BioHealth Capital Region Forum, gaining invaluable exposure and direct feedback from industry professionals. This platform is perfect for engaging with potential investors and accelerating your company’s visibility.

Prizes:

Additional Opportunities: The winning team will be featured on the BioTalk with Rich Bendis Podcast, further increasing their visibility within the biohealth community.

Read More
astrazeneca logo

AstraZeneca’s Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery

By News, News Archive

astrazeneca logoBased on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In this regimen, patients are treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.

Read More
Venture

Axios:Venture capitalists move toward “pay to play”

By News, News Archive

VentureVenture capitalists are inserting a record number of “pay to play” provisions into term sheets, according to new data from law firm Cooley.

Why it matters: This is a sharp-elbowed reminder that VCs are facing performance pressure, and that startups are having a tougher time getting funded.

Jargon watch: “Pay to play” provisions also may be known as “cram down” clauses, and basically are designed to benefit new investors at the expense of existing shareholders who don’t want to invest additional capital.

  • The critical view is that this is unfair to insiders who took a chance when the company’s prospects were more speculative, but who’ve either lost faith or no longer have money to spend (including early employees or VC funds without adequate reserves).
  • The more charitable view is that such rounds are for companies that need money — not those that just want to bolster balance sheets — and that the new investors are vital to the company’s future success. In short: Get on board or get out.
Read More
MoonShot

Biden-⁠Harris Administration Announces $150 Million from ARPA-H to Deliver Progress on Biden Cancer Moonshot Goals and Improve Health Outcomes

By News, News Archive

MoonShotMore than two years ago, President Joe Biden and First Lady Jill Biden reignited the Cancer Moonshot with the goals of reducing the cancer death rate in the United States by at least half—preventing more than 4 million cancer deaths—by 2047, and improving the experience of people who are touched by cancer. As part of this effort, President Biden and Vice President Harris secured bipartisan Congressional support to establish the Advanced Research Projects Agency for Health (ARPA-H) to generate breakthroughs in ways to prevent, detect, and treat cancer and other diseases. In its first two years, ARPA-H has invested more than $400 million to fast-track progress on how we prevent, detect, and treat cancer.

Read More
TEDCO

TEDCO Announces Kim Mozingo’s Promotion to Vice President, Federal Programs

By News, News Archive

TEDCOCOLUMBIA, Md., (August 13, 2024)TEDCO, Maryland’s economic engine for technology companies, is pleased to announce the promotion of Kim Mozingo to vice president of Federal Programs. In this role, Mozingo will lead a suite of seven programs designed to transform federal scientific research into economic growth and new job opportunities for Maryland’s small businesses.

“We are pleased to have such a dedicated individual as Kim on the TEDCO team,” said Stephen Auvil, chief federal engagement officer. “Under her leadership, TEDCO’s federal programs have experienced significant growth.  Her management of our SBIR Proposal Lab, DefTech, and other federal programs have supported more than 150 companies.  Moreover, she will be launching several new programs in her area over the next six months.  This promotion is well deserved and reflects her accomplishments and growing responsibilities.”

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.